08:55 AM EDT, 08/15/2024 (MT Newswires) -- The Centers for Medicare & Medicaid Services released Thursday the prices for the first 10 prescription drugs that were subject to negotiations between drugmakers and Medicare.

The negotiated prices will go into effect in 2026 and are expected to save Medicare enrollees about $1.5 billion, according to Medicare.

The negotiated prices compared with the 2023 list prices for the 10 drugs are as follows: Merck's ( MRK ) Januvia: $113 vs. $527; Novo Nordisk's ( NVO ) Fiasp and NovoLog: $119 vs. $495; AstraZeneca's ( AZN ) Farxiga: $178.50 vs. $556; Amgen's ( AMGN ) Enbrel: $2,355 vs. $7,106; Boehringer Ingelheim's Jardiance: $197 vs. $573; Johnson & Johnson's ( JNJ ) Stelara: $4,695 vs. $13,836; Johnson & Johnson's ( JNJ ) Xarelto: $197 vs $517; Bristol Myers Squibb's ( BMY ) Eliquis: $231 vs. $521; Novartis' ( NVS ) Entresto: $295 vs. $628; and AbbVie's ( ABBV ) Imbruvica: $9,319 vs. $14,934.

Price: 158.40, Change: -0.08, Percent Change: -0.05